A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1).

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514058-59-00

Acronym

BREAKPOINT

Enrollment

Registered

2024-07-29

Start date

2018-06-11

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors.

Brief summary

Progression Free Survival (PFS)

Detailed description

Overall Survival (OS), Objective Response Rates (ORR), Safety profile of the drug

Interventions

DRUGCABOZANTINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression Free Survival (PFS)	—

Secondary

Measure	Time frame
Overall Survival (OS), Objective Response Rates (ORR), Safety profile of the drug	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026